Small nucleolar RNA host gene 16 (SNHG16) (SNHG16)

Small nucleolar RNA host gene 16 (SNHG16) is a long non-coding RNA (lncRNA) located on chromosome 17q25.1 that has emerged as a significant oncogenic driver in numerous human malignancies [1, 2]. It primarily functions as a competitive endogenous RNA (ceRNA), acting as a "molecular sponge" for various tumor-suppressive microRNAs, thereby preventing them from silencing their target oncogenic mRNAs [2, 3]. Beyond its role as a miRNA sponge, SNHG16 can also interact with RNA-binding proteins and epigenetic modifiers, such as EZH2, to regulate gene expression at the transcriptional and post-transcriptional levels [3, 5]. Its overexpression is frequently associated with increased cell proliferation, migration, invasion, and resistance to apoptosis and chemotherapy, making it a valuable prognostic biomarker and a potential therapeutic target [1, 6]. In addition to its role in oncology, SNHG16 has been implicated in inflammatory processes, sepsis-induced acute lung injury, and renal fibrosis [5]. While no SNHG16-targeted therapies are currently approved, experimental approaches using antisense oligonucleotides and siRNA have shown promise in preclinical models by inhibiting tumor growth and restoring drug sensitivity [12, 13]. The high stability of SNHG16 in body fluids further supports its utility as a non-invasive diagnostic and prognostic marker [6]. Therapeutic challenges include the efficient delivery of RNA-targeting agents to tumor sites and the potential for off-target effects [1, 7].

Other names

ncRANASLNC20822Nbla10727Nbla12061Non-coding RNA expressed in aggressive neuroblastoma

SNHG16 primarily functions as a competitive endogenous RNA (ceRNA) by sponging various microRNAs, which prevents them from inhibiting their target mRNAs [2, 3]. It also acts as a scaffold or recruiter for epigenetic modifiers, such as EZH2, to the promoters of genes like p21, leading to transcriptional silencing [3, 5].